Close Menu
Home › About Us › Our Staff › Tony Fong

Tony Fong

Managing Editor, 360Dx
Phone Number
+1-212-651-5635
Email
tfong@genomeweb.com
Tony Fong at Genomeweb / 360dx Tony Fong at Genomeweb / 360dx

Tony Fong is managing editor for 360Dx, GenomeWeb's news site on the in vitro diagnostics market.

Articles Authored by Tony Fong

Jan 02, 2019

Mergers and Acquisitions in Dx Space Drop Sharply in 2018

Premium

A lack of attractive targets, high valuations, and a more attractive IPO market contributed to a 45 percent year-over-year decline in M&A.

Feb 05, 2018

With Eye on Pharma Partnerships, Rare Disease Dx Firm Centogene Looks to US Market

Premium

Centogene opened a Boston office in December and plans to open a lab there in a few months as it awaits an FDA decision on its clinical tool.

Dec 27, 2017

PAMA Looms Large as Clinical Labs Drive M&A Activity in Diagnostics Space in 2017

There were 58 M&A deals in the diagnostics space during the year, paced by Quest, which announced 12 deals. Abbott's $5.3 billion buy of Alere was the biggest acquisition. 

Oct 17, 2017

NJIT Researchers Developing Biochip to Potentially Detect Cancer, Other Diseases in 1 Minute

Premium

Researchers at NJIT have initially tested their biochip for the detection of early-stage ovarian cancer, but they said it could have use for other cancers and diseases.

Aug 24, 2017

University of Illinois Team Develops Smartphone Diagnostic Tool as Alternative to Immunoassays

Premium

The University of Illinois team developed the technology with an eye at low-resource settings, including developing nations and rural communities. 

Jul 31, 2017

Anticipating Approvals in China, VoxelCloud Leveraging AI Technology for Diagnostics

Premium

The firm anticipates receiving regulatory approval from the CFDA for its first three products by the end of the year, including one for lung cancer.

May 30, 2017

Q&A: Winship Cancer Institute's Dan Brat on the Challenges of Using MDx for Cancer

Premium

Winship's director of the cancer tissue and pathology shared resource said that some labs aren't leveraging molecular technologies due to reimbursement issues. 

May 30, 2017

The PAMA Effect: Consolidation of Clinical Labs Expected as Legislation Set to Take Effect

With PAMA scheduled to be implemented in January, many believe M&A in the clinical lab space will heat up, with Quest and LabCorp the main beneficiaries. 

Apr 27, 2017

Q&A: Sentara's Tabetha Sundin on the Challenges of Molecular Technology in the Clinic

While molecular testing is now routine in cancer and women's health, for other disease areas, the technology may be overkill, Sundin said. 

Mar 13, 2017

With a New Name, Metabolic Dx Firm Nightingale Preps for Market Launch

Premium

The three-year-old firm anticipates entering the clinical space later this year with a launch of its metabolomics-based test in Finland.

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.